An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...
Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...
and developability comparable to the commercial therapeutic antibody Atezolizumab. Additionally, antibodies designed for EGFR(S468R) displayed exceptional specificity, precisely distinguishing the ...
De novo antibody design has been one of the major challenges in AI-based drug discovery, requiring atomic-level precision to ...
Zacks Investment Research on MSN6h
FDA Expands Exelixis Cabometyx Label for Neuroendocrine TumorsExelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback